: Limiting high-molecular-weight aggregates and low-molecular-weight fragments to prevent immunogenic reactions. 2. Upstream Process Development: Maximizing Titers
Centrifugation (depth filtration as backup) → 0.2 µm filtration.
Final titer = 4.2 g/L, viability >75% at harvest. A 2.5-fold improvement over initial process.
If you are interested in hearing more about specific parts of this process, I can tell you more about: The specific used How we scale up from benchtop to commercial production The regulatory requirements for this process A Mab A Case Study In Bioprocess Development
The primary goal of upstream development is to maximize volumetric productivity while ensuring the critical quality attributes (CQAs) of the mAb remain within predefined limits. Cell Line Development
An ultra-high-capacity Protein A resin was implemented for initial product capture. Loaded at
Defines the clinical goals, including safety, efficacy, and dosage. Critical Quality Attributes (CQAs): Final titer = 4
The primary goal of this development program was to transition mAb-X from a discovery-phase lead candidate into a commercially viable manufacturing process. Process Goals Achieve an upstream harvest titer of > 5.0 g/L. Purity: Ensure monomer content with host cell protein (HCP)
The bioprocess for A Mab was developed and optimized through a series of experiments and studies. The process involved the following steps:
The final step in the bioprocess development of A Mab was the development of a stable formulation. A Mab was formulated in a buffer containing a stabilizer, a surfactant, and a polysorbate. The formulation was optimized to achieve: Cell Line Development An ultra-high-capacity Protein A resin
The purification process was scaled up from a 10 mL to a 100 L scale, demonstrating excellent scalability.
High-throughput automated single-cell deposition was used to ensure clonality, fulfilling strict regulatory requirements. Media and Feed Optimization
By dissecting the successes and challenges of case studies like A-mAb, the industry not only builds better processes for today’s blockbuster drugs but also forges the tools and knowledge necessary to develop the complex biologics of tomorrow, ensuring that transformative therapies can reach the patients who need them most.